Does the hedgehog pathway inhibitor GDC-0449 show potential in skin and other cancers?
Long-term efficacy and safety studies of GDC-0449 in these conditions and other solid cancers are now underway. These clinical trials with GDC-0449, and trials with other hedgehog inhibitors, will reveal whether it is beneficial and safe to inhibit the hedgehog pathway in a wide range of solid tumours or not.
Catheter-directed GACE can suppress the appetite hormone ghrelin and affect weight gain.